DK0729509T3 - Vaccine imod fåresyge indeholdende en Jeryl-Lynn virus-stamme - Google Patents

Vaccine imod fåresyge indeholdende en Jeryl-Lynn virus-stamme

Info

Publication number
DK0729509T3
DK0729509T3 DK95900751T DK95900751T DK0729509T3 DK 0729509 T3 DK0729509 T3 DK 0729509T3 DK 95900751 T DK95900751 T DK 95900751T DK 95900751 T DK95900751 T DK 95900751T DK 0729509 T3 DK0729509 T3 DK 0729509T3
Authority
DK
Denmark
Prior art keywords
jeryl
virus strain
vaccine against
mumps
lynn
Prior art date
Application number
DK95900751T
Other languages
Danish (da)
English (en)
Inventor
J Didelez
B D A Colau
Nigel Maurice Harford
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939323820A external-priority patent/GB9323820D0/en
Priority claimed from GB9406480A external-priority patent/GB9406480D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Application granted granted Critical
Publication of DK0729509T3 publication Critical patent/DK0729509T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0015—Combination vaccines based on measles-mumps-rubella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18721—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18761—Methods of inactivation or attenuation
    • C12N2760/18762—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36211—Rubivirus, e.g. rubella virus
    • C12N2770/36234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK95900751T 1993-11-19 1994-11-15 Vaccine imod fåresyge indeholdende en Jeryl-Lynn virus-stamme DK0729509T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939323820A GB9323820D0 (en) 1993-11-19 1993-11-19 Vaccine
GB9406480A GB9406480D0 (en) 1994-03-31 1994-03-31 Vaccine

Publications (1)

Publication Number Publication Date
DK0729509T3 true DK0729509T3 (da) 2004-08-16

Family

ID=26303889

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95900751T DK0729509T3 (da) 1993-11-19 1994-11-15 Vaccine imod fåresyge indeholdende en Jeryl-Lynn virus-stamme

Country Status (19)

Country Link
US (4) US6024962A (fr)
EP (2) EP1484391A1 (fr)
JP (1) JPH09504954A (fr)
KR (1) KR100362051B1 (fr)
CN (2) CN101948816A (fr)
AT (1) ATE266090T1 (fr)
AU (1) AU687922B2 (fr)
CA (1) CA2176929C (fr)
CY (2) CY2540B1 (fr)
DE (3) DE69433760T2 (fr)
DK (1) DK0729509T3 (fr)
ES (1) ES2219658T3 (fr)
LU (1) LU91458I2 (fr)
NL (1) NL300336I2 (fr)
NZ (1) NZ276102A (fr)
PT (1) PT729509E (fr)
SG (1) SG52780A1 (fr)
SI (1) SI0729509T1 (fr)
WO (1) WO1995014083A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT729509E (pt) 1993-11-19 2004-09-30 Glaxosmithkline Biolog Sa Vacina contra papeira contendo uma estirpe do virus jerryl-lynn
JP2003506039A (ja) * 1999-08-02 2003-02-18 ワイス ｃＤＮＡからの流行性耳下腺炎ウイルスのレスキュー
MX2017012389A (es) * 2015-03-27 2018-09-19 Cadila Healthcare Ltd Vacuna del virus de la parotiditis recombinante jeryl lynn2.
US20220023413A1 (en) * 2018-12-12 2022-01-27 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Recombinant mumps virus vaccine expressing genotype g fusion and hemagglutinin-neuraminidase proteins
RU2750818C1 (ru) * 2020-11-19 2021-07-05 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова Вирусный штамм для получения аттенуированной живой культуральной вакцины для профилактики и лечения опоясывающего герпеса для взрослого населения
CN114457046A (zh) * 2022-02-16 2022-05-10 科兴（大连）疫苗技术有限公司 一种稀释法传代纯化腮腺炎病毒的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3555149A (en) 1968-07-05 1971-01-12 Merck & Co Inc Mumps vaccine and its preparation
US4337242A (en) 1980-02-05 1982-06-29 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
JP3026029B2 (ja) * 1991-04-26 2000-03-27 財団法人阪大微生物病研究会 組換え水痘ウイルスとその作製法
PT729509E (pt) 1993-11-19 2004-09-30 Glaxosmithkline Biolog Sa Vacina contra papeira contendo uma estirpe do virus jerryl-lynn

Also Published As

Publication number Publication date
KR960705919A (ko) 1996-11-08
AU687922B2 (en) 1998-03-05
KR100362051B1 (ko) 2003-04-11
HK1012421A1 (en) 1999-07-30
CN1150819A (zh) 1997-05-28
EP0729509A1 (fr) 1996-09-04
NL300336I2 (nl) 2009-01-05
EP1484391A1 (fr) 2004-12-08
CN101948816A (zh) 2011-01-19
US20040120969A1 (en) 2004-06-24
DE122007000003I1 (de) 2007-05-24
ES2219658T3 (es) 2004-12-01
JPH09504954A (ja) 1997-05-20
PT729509E (pt) 2004-09-30
DE69433760T2 (de) 2005-05-12
CY2540B1 (en) 2006-06-28
US20020018784A1 (en) 2002-02-14
US6899884B2 (en) 2005-05-31
LU91458I2 (fr) 2008-08-25
NL300336I1 (nl) 2008-04-01
NZ276102A (en) 1998-04-27
DE69433760D1 (de) 2004-06-09
CY2008005I2 (el) 2018-01-10
AU8144194A (en) 1995-06-06
SG52780A1 (en) 1998-09-28
CY2008005I1 (el) 2012-01-25
CA2176929C (fr) 2002-04-30
ATE266090T1 (de) 2004-05-15
US6024962A (en) 2000-02-15
US20030095984A1 (en) 2003-05-22
US6656476B2 (en) 2003-12-02
CA2176929A1 (fr) 1995-05-26
WO1995014083A1 (fr) 1995-05-26
SI0729509T1 (en) 2004-08-31
EP0729509B1 (fr) 2004-05-06
DE122007000003I2 (de) 2011-01-13

Similar Documents

Publication Publication Date Title
DE69333814D1 (de) Genetischer impfstoff gegen den immunschwäche virus
MX9206574A (es) Proteina hibrida para la prevencion de infecciones de malaria y vacunas que la contienen.
HUP9901901A2 (hu) Hepatitis C elleni vakcinák
ATE141946T1 (de) Hiv-2-virusvarianten
DK1021547T3 (da) Vaccineformuleringer indeholdende papillomviruskapsomer og fremgangsmåder til anvendelse heraf
DE3278344D1 (en) Stabilization of influenza virus vaccine
ATE196773T1 (de) Infektiösen bronchitis virus 4/91 enthaltender geflügel-impfstoff
DK0745387T3 (da) Adjuvanser til virale vacciner
ATE105334T1 (de) Schimaerische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3.
WO1998013500A3 (fr) Virus mva de recombinaison exprimant des antigenes du virus de dengue et utilisation de ces derniers dans des vaccins
NL300336I1 (nl) Vaccin tegen de bof dat een jeryl-lynn virusstam bevat
AU580059B2 (en) Vaccine against rabies and preparation process thereof
TW377373B (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline infectious peritonitis virus disease
NO983946D0 (no) Parapoksyviruser inneholdende fremmed DNA, fremstilling og anvendelse derav i vaksiner
DK0838222T3 (da) Vaccinesammensætninger, der omfatter inaktiverede immunogener og levende kyllingeanæmi-virus (CAV)
FR2693655B1 (fr) Vaccin antirabique avirulent.
ATE530563T1 (de) Rekombinante proteine einer pakistanischen hepatitis e variante und ihre verwendung in diagnoseverfahren und impfungen
EP0563288A4 (en) Immunopotentiation of vaccines, particularly swine pleuropneumonia vaccines
EP0721782A3 (fr) Vaccin contre la grippe contenant de la toxine de pertussis
NZ316110A (en) vaccine containing an antigen from H. Influenzae and an antigen from influenza virus